Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Net Cash Flow (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Net Cash Flow for 6 consecutive years, with -$7.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 105.65% to -$7.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$47.1 million, a 161.63% decrease, with the full-year FY2025 number at -$47.1 million, down 161.63% from a year prior.
  • Net Cash Flow was -$7.7 million for Q4 2025 at PROCEPT BioRobotics, up from -$8.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $161.3 million in Q3 2021 to a low of -$40.9 million in Q1 2023.
  • A 5-year average of $9.4 million and a median of -$15.3 million in 2021 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 767.36% in 2023; the steepest drop was 140.58% in 2023.
  • PROCEPT BioRobotics' Net Cash Flow stood at -$16.2 million in 2021, then crashed by 69.25% to -$27.4 million in 2022, then fell by 12.0% to -$30.6 million in 2023, then soared by 546.98% to $137.0 million in 2024, then plummeted by 105.65% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Net Cash Flow are -$7.7 million (Q4 2025), -$8.4 million (Q3 2025), and -$13.5 million (Q2 2025).